Cancers & treatments·Regimen libraryNeoadjuvant

TCHP

Checked 2026-09-09

Stage II-III HER2-positive breast cancer, neoadjuvant

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6, then HP to complete 1 year (about 18 weeks)Intravenous

Components

Drug	Dose	Route	Days
Docetaxel Cytotoxic chemotherapy (taxane)	75 mg/m²	IV	D1
Carboplatin Cytotoxic chemotherapy (platinum)	AUC 6	IV	D1
Trastuzumab Monoclonal antibody (anti-HER2)	8 mg/kg loading then 6 mg/kg	IV	D1
Pertuzumab Monoclonal antibody (anti-HER2, dimerisation domain)	840 mg loading then 420 mg	IV	D1

Cycles

6, then HP to complete 1 year

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Recommended

Notes

Diarrhoea is the limiting toxicity; carboplatin AUC 6 is often reduced to AUC 5.
DESTINY-Breast11 (T-DXd × 4 then THP) reported a higher pCR than ddAC-THP and is entering guidelines.

Used in

HER2-positive breast cancer

Trials

DESTINY-Breast11

Products

DocetaxelCarboplatinTrastuzumabPertuzumab

Source

TRYPHAENA, Ann Oncol 2013; NCCN Breast Cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.